A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells

British Journal of Haematology

Volumn 142, Issue 4, 2008, Pages 583-594

  Makishi, Shoko ^a   Okudaira, Taeko ^a   Ishikawa, Chie ^a   Sawada, Shigeki ^a   Watanabe, Toshiki ^b   Hirashima, Mitsuomi ^c   Sunakawa, Hajime ^a   Mori, Naoki ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

AP 1; Burkitt lymphoma; Galectin 9; Hodgkin lymphoma; NF B

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 4; ECALECTIN; GALAPTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN TYROSINE PHOSPHATASE; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CELL CULTURE; CELL CYCLE ARREST; CELL GROWTH; CELL LINE; CELL SURVIVAL; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; GENETIC CODE; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNITY; ONCOGENE C MYC; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REED STERNBERG CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TH1 CELL; WESTERN BLOTTING;

APOPTOSIS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CASPASES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; GALECTINS; HODGKIN DISEASE; HUMANS; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 47649118999     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07229.x     Document Type: Article

References (56)

1. Arbel-Goren, R., Levy, Y., Ronen, D. Zick, Y. (2005) Cyclin-dependent kinase inhibitors and JNK act as molecular switches, regulating the choice between growth arrest and apoptosis induced by galectin-8. Journal of Biological Chemistry, 280, 19105 19114.
2. Bargou, R.C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M.Y., Arnold, W., Royer, H.D., Grinstein, E., Greiner, A., Scheidereit, C. Dörken, B. (1997) Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. Journal of Clinical Investigation, 100, 2961 2969.
3. Bi, S., Earl, L.A., Jacobs, L. Baum, L.G. (2008) Structural features of galectin-9 and galectin-1 that determine distinct T cell death pathways. Journal of Biochemistry, 283, 12248 12258.
4. van den Bosch, C.A. (2004) Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter? The Lancet Oncology, 5, 738 746.
5. Bremer, E., van Dam, G., Kroesen, B.J., de Leij, L. Helfrich, W. (2006) Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends in Molecular Medicine, 12, 382 393.
6. Brooks, A.R., Shiffman, D., Chan, C.S., Brooks, E.E. Milner, P.G. (1996) Functional analysis of the human cyclin D2 and cyclin D3 promoters. Journal of Biological Chemistry, 271, 9090 9099.
7. Chen, Z.J., Parent, L. Maniatis, T. (1996) Site-specific phosphorylation of IκBα by a novel ubiquitination-dependent protein kinase activity. Cell, 84, 853 862.
8. Chu, Z.L., McKinsey, T.A., Liu, L., Gentry, J.J., Malim, M.H. Ballard, D.W. (1997) Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-κB control. Proceedings of the National Academy of Sciences of the United States of America, 94, 10057 10062.
9. Cooper, D.N. Barondes, S.H. (1999) God must love galectins; he made so many of them. Glycobiology, 9, 979 984.
10. Deveraux, Q.L., Roy, N., Stennicke, H.R., Van Arsdale, T., Zhou, Q., Srinivasula, S.M., Alnemri, E.S., Salvesen, G.S. Reed, J.C. (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO Journal, 17, 2215 2223.
11. Diehl, V., Thomas, R.K. Re, D. (2004) Hodgkin's lymphoma-diagnosis and treatment. The Lancet Oncology, 5, 19 26.
12. Dolcet, X., Llobet, D., Pallares, J. Matias-Guiu, X. (2005) NF-kB in development and progression of human cancer. Virchows Archiv, 446, 475 482.
13. Duyao, M.P., Buckler, A.J. Sonenshein, G.E. (1990) Interaction of an NF-κB-like factor with a site upstream of the c-myc promoter. Proceedings of the National Academy of Sciences of the United States of America, 87, 4727 4731.
14. Griffin, J. (2001) The biology of signal transduction inhibition: basic science to novel therapies. Seminars in Oncology, 28, 3 8.
15. Hernandez, J.D. Baum, L.G. (2002) Ah, sweet mystery of death! Galectins and control of cell fate. Glycobiology, 12, 127R 136R.
16. Hess, J., Angel, P. Schorpp-Kistner, M. (2004) AP-1 subunits: quarrel and harmony among siblings. Journal of Cell Science, 117, 5965 5973.
17. 1-to-S-phase transition. Molecular and Cellular Biology, 19, 2690 2698.
18. Huang, Y., Ohtani, K., Iwanaga, R., Matsumura, Y. Nakamura, M. (2001) Direct trans-activation of the human cyclin D2 gene by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene, 20, 1094 1102.
19. Hussain, A., Doucet, J.-P., Gutiérrez, M., Ahmad, M., Al-Hussein, K., Capello, D., Gaidano, G. Bhatia, K. (2003) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas apoptosis in Burkitt's lymphomas with loss of multiple pro-apoptotic proteins. Haematologica, 88, 167 175.
20. Iwanaga, R., Ohtani, K., Hayashi, T. Nakamura, M. (2001) Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene, 20, 2055 2067.
21. Izban, K.F., Ergin, M., Huang, Q., Qin, J.-Z., Martinez, R.L., Schnitzer, B., Ni, H., Nickoloff, B.J. Alkan, S. (2001) Characterization of NF-κB expression in Hodgkin's disease: inhibition of constitutively expressed NF-κB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Modern Pathology, 14, 297 310.
22. Jazirehi, A.R. Bonavida, B. (2005) Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene, 24, 2121 2143.
23. Jazirehi, A.R., Huerta-Yepez, S., Cheng, G. Bonavida, B. (2005) Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-κB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Research, 65, 264 276.
24. Jost, P.J. Ruland, J. (2007) Aberrant NF-κB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood, 109, 2700 2707.
25. Kawakami, H., Tomita, M., Matsuda, T., Ohta, T., Tanaka, Y., Fujii, M., Hatano, M., Tokuhisa, T. Mori, N. (2005) Transcriptional activation of survivin through the NF-κB pathway by human T-cell leukemia virus type I Tax. International Journal of Cancer, 115, 967 974.
26. Kimura, N., Miyakawa, Y., Kohmura, K., Umezawa, K., Ikeda, Y. Kizaki, M. (2007) Targeting NF-κB and induction of apoptosis by novel NF-κB inhibitor dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. Leukemia Research, 31, 1529 1535.
27. Kube, D., Holtick, U., Vockerodt, M., Ahmadi, T., Haier, B., Behrmann, I., Heinrich, P.C., Diehl, V. Tesch, H. (2001) STAT3 is constitutively activated in Hodgkin cell lines. Blood, 98, 762 770.
28. Liu, F.T. (2000) Galectins: a new family of regulators of inflammation. Clinical Immunology, 97, 79 88.
29. Liu, F.T., Patterson, R.J. Wang, J.L. (2002) Intracellular functions of galectins. Biochimica et Biophysica Acta, 1572, 263 273.
30. Lu, L.-H., Nakagawa, R., Kashio, Y., Ito, A., Shoji, H., Nishi, N., Hirashima, M., Yamauchi, A. Nakamura, T. (2007) Characterization of galectin-9-induced death of Jurkat T cells. Journal of Biochemistry, 141, 157 172.
31. Mathas, S., Lietz, A., Janz, M., Hinz, M., Jundt, F., Scheidereit, C., Bommert, K. Dörken, B. (2003) Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood, 102, 1028 1034.
32. Matsumoto, R., Matsumoto, H., Seki, M., Hata, M., Asano, Y., Kanegasaki, S., Stevens, R.L. Hirashima, M. (1998) Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. Journal of Biological Chemistry, 273, 16976 16984.
33. Matsushita, N., Nishi, N., Seki, M., Matsumoto, R., Kuwabara, I., Liu, F.-T., Hata, Y., Nakamura, T. Hirashima, M. (2000) Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. Journal of Biological Chemistry, 275, 8355 8360.
34. Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E.A., Coyle, A.J., Sobel, R.A., Freeman, G.J. Kuchroo, V.K. (2002) Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 415, 536 541.
35. Mori, N., Fujii, M., Ikeda, S., Yamada, Y., Tomonaga, M., Ballard, D.W. Yamamoto, N. (1999) Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood, 93, 2360 2368.
36. Mounier, N., Spina, M. Gisselbrecht, C. (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. British Journal of Haematology, 136, 685 698.
37. Mouzakiti, A. Packham, G. (2003) Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. British Journal of Haematology, 122, 61 69.
38. Nguyen, P.L., Harris, N.L., Ritz, J. Robertson, M.J. (1996) Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. American Journal of Pathology, 148, 847 853.
39. Nishi, N., Itoh, A., Fujiyama, A., Yoshida, N., Araya, S., Hirashima, M., Shoji, H. Nakamura, T. (2005) Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Letters, 579, 2058 2064.
40. Okudaira, T., Hirashima, M., Ishikawa, C., Makishi, S., Tomita, M., Matsuda, T., Kawakami, H., Taira, N., Ohshiro, K., Masuda, M., Takasu, N. Mori, N. (2007) A modified version of galectin-9 suppresses cell growth and induces apoptosis of human T-cell leukemia virus type I-infected T-cell lines. International Journal of Cancer, 120, 2251 2261.
41. 2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and down-regulation of antiapoptotic proteins. Blood, 105, 1750 1758.
42. Rabinovich, G.A. (1999) Galectins: an evolutionarily conserved family of animal lectins with multifunctional properties; a trip from the gene to clinical therapy. Cell Death and Differentiation, 6, 711 721.
43. Seth, A., Zhang, C., Letvin, N.L. Schlossman, S.F. (1997) Detection of apoptotic cells from peripheral blood of HIV-infected individuals using a novel monoclonal antibody. AIDS, 11, 1059 1061.
44. Sevilla, L., Zaldumbide, A., Pognonec, P. Boulukos, K.E. (2001) Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFκB, STAT and AP1 transcription factor families. Histolology and Histopathology, 16, 595 601.
45. Shaulian, E. Karin, M. (2001) AP-1 in cell proliferation and survival. Oncogene, 20, 2390 2400.
46. Shin, S., Sung, B.-J., Cho, Y.-S., Kim, H.-J., Ha, N.-C., Hwang, J.-I., Chung, C.-W., Jung, Y.-K. Oh, B.-H. (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry, 40, 1117 1123.
47. Stehlik, C., de Martin, R., Kumabashiri, I., Schmid, J.A., Binder, B.R. Lipp, J. (1998) Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor α-induced apoptosis. Journal of Experimental Medicine, 188, 211 216.
48. Stillman, B.N., Hsu, D.K., Pang, M., Brewer, C.F., Johnson, P., Liu, F.-T. Baum, L.G. (2006) Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. Journal of Immunology, 176, 778 789.
49. high thymocyte subpopulation. Glycobiology, 17, 1404 1412.
50. Türeci, O., Schmitt, H., Fadle, N., Pfreundschuh, M. Sahin, U. (1997) Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. Journal of Biological Chemistry, 272, 6416 6422.
51. Wada, J., Ota, K., Kumar, A., Wallner, E.I. Kanwar, Y.S. (1997) Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. Journal of Clinical Investigation, 99, 2452 2461.
52. Watanabe, M., Dewan, M.Z., Taira, M., Shoda, M., Honda, M., Sata, T., Higashihara, M., Kadin, M.E., Watanabe, T., Yamamoto, N., Umezawa, K. Horie, R. (2007) IκBα independent induction of NF-κB and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. Laboratory Investigation, 87, 372 382.
53. Weber-Nordt, R.M., Egen, C., Wehinger, J., Ludwig, W., Gouilleux-Gruart, V., Mertelsmann, R. Finke, J. (1996) Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood, 88, 809 816.
54. Zhang, C., Ao, Z., Seth, A. Schlossman, S.F. (1996) A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells. Journal of Immunology, 157, 3980 3987.
55. Zheng, B., Georgakis, G.V., Li, Y., Bharti, A., McConkey, D., Aggarwal, B.B. Younes, A. (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clinical Cancer Research, 10, 3207 3215.
56. Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., Zheng, X.X., Strom, T.B. Kuchroo, V.K. (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunology, 6, 1245 1252.